Alemtuzumab: effective monotherapy for simultaneous B-cell chronic lymphocytic leukaemia and Sézary syndrome.
The simultaneous presentation of chronic lymphocytic leukaemia (CLL) and cutaneous T-cell lymphoma (CTCL) is a very rare occurrence where optimal treatment is unknown. We present the case of a 65-yr-old man who was successfully treated with alemtuzumab monotherapy for both disorders, but at a cost of severe infectious morbidity and prolonged pancytopenia.
Gibbs
Simon D J
SD
Haematology Service, Peter MacCallum Cancer Centre, Melbourne, Australia.
Herbert
Kirsten E
KE
McCormack
Christopher
C
Seymour
John F
JF
Prince
H Miles
HM
D020095:Absidia; D000368:Aged; D000074323:Alemtuzumab; D000890:Anti-Infective Agents / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm / Q000627:therapeutic use*; D001228:Aspergillosis / Q000188:drug therapy / Q000209:etiology; D002481:Cellulitis / Q000209:etiology; D003586:Cytomegalovirus Infections / Q000188:drug therapy / Q000209:etiology; D006801:Humans; D007116:Immunization, Passive / Q000009:adverse effects; D016867:Immunocompromised Host; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000628:therapy*; D008297:Male; D009091:Mucormycosis / Q000188:drug therapy / Q000209:etiology; D009378:Neoplasms, Multiple Primary / Q000628:therapy*; D010198:Pancytopenia / Q000209:etiology; D012074:Remission Induction; D012751:Sezary Syndrome / Q000628:therapy*; D012852:Sinusitis / Q000209:etiology
D000890:Anti-Infective Agents; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm; D000074323:Alemtuzumab